Simplex Trading, LLC Seagen Inc. Transaction History

Simplex Trading, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$187.64 - $206.25 $1.03 Million - $1.13 Million	5,493 Added 903.45%	6,101 $1.17 Million
Q1 2023 Apr 27, 2023	SELL	$127.59 - $203.08 $469,276 - $746,928	-3,678 Reduced 85.81%	608 $123,000
Q4 2022 Feb 02, 2023	SELL	$117.37 - $139.17 $388,142 - $460,235	-3,307 Reduced 43.55%	4,286 $550,000
Q3 2022 Nov 04, 2022	SELL	$135.27 - $180.11 $2.19 Million - $2.92 Million	-16,213 Reduced 68.1%	7,593 $1.04 Million
Q2 2022 Aug 03, 2022	BUY	$108.81 - $179.33 $1.81 Million - $2.97 Million	16,589 Added 229.86%	23,806 $4.21 Million

Q1 2022 May 02, 2022	BUY	$119.61 - $157.85 $660,606 - $871,805	5,523 Added 326.03%	7,217 $1.04 Million
Q4 2021 Feb 23, 2022	SELL	$142.57 - $190.86 $743,787 - $995,716	-5,217 Reduced 75.49%	1,694 $261,000
Q3 2021 Oct 28, 2021	SELL	$142.45 - $169.82 $71,225 - $84,910	-500 Reduced 6.75%	6,911 $1.09 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $446,034 - $531,952	3,302 Added 80.36%	7,411 $1.17 Million
Q1 2021 Apr 26, 2021	BUY	$137.51 - $190.8 $334,836 - $464,598	2,435 Added 145.46%	4,109 $570,000
Q4 2020 Feb 02, 2021	BUY	$164.63 - $211.93 $275,590 - $354,770	1,674 New	1,674 $0

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.